Stable Isotope Pharmaceutical Composition for Inflammation Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing therapies struggle to effectively target chronic inflammation and oxidative stress without disrupting their normal physiological functions.
Innovation Solution
A pharmaceutical composition utilizing enriched stable isotopes of chemical elements such as H, Li, C, B, N, O, Mg, Si, S, K, Cl, Ca, V, Cr, Fe, Ni, Cu, Zn, Sr, Mo, Se, Ge, Ga, Br, Rb, Ag, and Ba, administered in elemental, atomic, or colloidal form, to modulate inflammation and oxidative stress by altering their natural isotopic ratios.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If conventional anti-inflammatory drugs and antioxidants are administered, then inflammation and oxidative stress are reduced, but normal physiological functions are disrupted
Solution Approach 1:
The patent changes the isotopic composition parameter of essential elements (enriching in lighter isotopes such as 12C, 14N, 16O, 1H) to modulate biological processes. This parameter change allows selective intervention in pathological processes (inflammation and oxidative stress) while preserving normal physiological functions that depend on natural isotopic ratios
Solution Approach 2:
The invention applies local quality by targeting specific isotopic compositions in affected tissues and cells. By enriching lighter isotopes in essential elements, the therapy creates localized isotopic gradients that preferentially affect pathological processes in inflamed or oxidatively stressed tissues without disrupting systemic physiological functions
2Object-affected harmful factors
If enriched stable isotopes are administered, then inflammation and oxidative stress are effectively targeted, but manufacturing complexity increases
Solution Approach 1:
The patent specifies precise isotopic enrichment parameters (minimum percentages of lighter isotopes for each element) that balance therapeutic efficacy with manufacturing feasibility. These parameter specifications provide clear targets for isotope enrichment processes while maintaining effectiveness in reducing inflammation and oxidative stress
Data Source
AI summary
Disclosed are therapeutic compositions of matter for use in regulation of local and systemic inflammation and reduction of oxidative stress to enable discovery and development of more effective pharmaceutical agents, organic compounds, and other medicinal formulations.